[Medication of the month. Topical pimecrolimus (Elidel)].
Pimecrolimus inhibits some specific steps of the Th1 and Th2 immune reactions. It belongs to the class of ascomycin macrolactams. The topical drug formulation targets cutaneous inflammation, more particularly lymphocytes and mast cells without impairing systemic immunosurveillance. Topical applications are indicated for treating atopic dermatitis. In this indication, it represents an alternative or an adjuvant drug to topical corticosteroids. The treatment of other dermatoses could also benefit from pimecrolimus.
CHR hutois, Service de Dermatologie, Huy.
P
P
Quatresooz
I
I
Fumal
C
C
Piérard-Franchimont
G E
GE
Piérard
D000279:Administration, Cutaneous; D065095:Calcineurin Inhibitors; D003876:Dermatitis, Atopic / Q000188:drug therapy; D003879:Dermatologic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019696:Peptidylprolyl Isomerase / Q000037:antagonists & inhibitors; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use
D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; C117268:pimecrolimus; D019696:Peptidylprolyl Isomerase; D016559:Tacrolimus